Jean-François Dedieu

616 total citations
15 papers, 485 citations indexed

About

Jean-François Dedieu is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Jean-François Dedieu has authored 15 papers receiving a total of 485 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Oncology and 3 papers in Genetics. Recurrent topics in Jean-François Dedieu's work include Cancer Treatment and Pharmacology (4 papers), Virus-based gene therapy research (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Jean-François Dedieu is often cited by papers focused on Cancer Treatment and Pharmacology (4 papers), Virus-based gene therapy research (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Jean-François Dedieu collaborates with scholars based in France, United States and Belgium. Jean-François Dedieu's co-authors include Michel Perricaudet, Emmanuelle Vigne, Patrice Yeh, Aude Le Roux, Dermot Walls, Catherine Le Jossic-Corcos, Nicolas Ferry, Christian Bréchot, Michel Perricaudet and Patrick Arbuthnot and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Brain.

In The Last Decade

Jean-François Dedieu

15 papers receiving 476 citations

Peers

Countries citing papers authored by Jean-François Dedieu

Since Specialization

Citations

This map shows the geographic impact of Jean-François Dedieu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean-François Dedieu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean-François Dedieu more than expected).

Fields of papers citing papers by Jean-François Dedieu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean-François Dedieu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean-François Dedieu. The network helps show where Jean-François Dedieu may publish in the future.

Co-authorship network of co-authors of Jean-François Dedieu

This figure shows the co-authorship network connecting the top 25 collaborators of Jean-François Dedieu. A scholar is included among the top collaborators of Jean-François Dedieu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean-François Dedieu. Jean-François Dedieu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial 2022 ·Brain ·Raphael Schiffmann, Timothy M. Cox, Jean-François Dedieu, Sebastiaan J.M. Gaemers, Julia B. Hennermann, Hiroyuki Ida, Eugen Mengel, Pascal Minini, Pramod K. Mistry, Petra B. Musholt, David Scott, Jyoti Sharma, Michel Peterschmitt	26
2	Venglustat combined with imiglucerase positively affects neurological features and brain connectivity in adults with Gaucher disease type 3 2021 ·Molecular Genetics and Metabolism ·Raphael Schiffmann, Timothy M. Cox, Jean-François Dedieu, Sebastiaan J.M. Gaemers, Julia B. Hennermann, Hiroyuki Ida, Eugen Mengel, Pramod K. Mistry, Petra B. Musholt, Jyoti Sharma, Bingzhi Zhang, (unknown)	1
3	A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors 2017 ·Investigational New Drugs ·Janice M. Mehnert, Gerald M. Edelman, Mark N. Stein, (unknown), Joanne Lager, Jean-François Dedieu, (unknown), Jyoti Sharma, Li Liu, Patricia LoRusso	11
4	Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma 2016 ·Cancer Chemotherapy and Pharmacology ·Oliver Bechter, Herlinde Dumez, (unknown), Kevin Punie, Karl Hsu, Jean-François Dedieu, (unknown), Elisa Francesconi, Jyoti Sharma, Li Liu, Patrick Schöffski	4
5	Phase I safety and pharmacokinetic (PK) dose escalation study with SAR245408 (S) polymorph E, a PI3K inhibitor, in patients (pts) with solid tumors or lymphoma. 2015 ·Journal of Clinical Oncology ·Oliver Bechter, Herlinde Dumez, (unknown), Kevin Punie, Li Liu, Jason Jiang, Jean-François Dedieu, Patrick Schöffski	1
6	Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors 2014 ·Investigational New Drugs ·A. Craig Lockhart, (unknown), John Sarantopoulos, Monica Mita, Andrea Wang‐Gillam, Jennifer L. Moseley, (unknown), (unknown), (unknown), Laurent Kassalow, Jean-François Dedieu, Alain C. Mita	8
7	Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel 2014 ·Cancer Chemotherapy and Pharmacology ·John Sarantopoulos, Alain C. Mita, James L. Wade, John C. Morris, Olivier Rixe, Monica Mita, Jean-François Dedieu, (unknown), Laurent Kassalow, A. Craig Lockhart	12
8	Phase I trial of cabazitaxel plus cisplatin in patients with advanced solid tumors. 2012 ·Journal of Clinical Oncology ·A. Craig Lockhart, (unknown), John Sarantopoulos, Monica Mita, (unknown), Jennifer L. Moseley, Jean-François Dedieu, (unknown), (unknown), (unknown), Alain C. Mita	4
9	Local Gene Transfer and Expression Following Intramuscular Administration of FGF-1 Plasmid DNA in Patients With Critical Limb Ischemia 2009 ·Molecular Therapy ·Iris Baumgärtner, Nicolas Chronos, Anthony J. Comerota, Timothy D. Henry, (unknown), (unknown), Anne Caron, Jean-François Dedieu, (unknown), P. Delaère	42
10	Hypothalamic-pituitary-adrenocortical and gonadal axes and sympathoadrenal activity of adult male rats prenatally exposed to morphine 1999 ·Neuroscience Letters ·Isabelle Dutriez-Casteloot, François Bernet, Jean-François Dedieu, Dominique Croix, Christine Laborie, Valérie Montel, Jean Lésage, Jean‐Claude Beauvillain, Jean‐Paul Dupouy	19
11	RGD Inclusion in the Hexon Monomer Provides Adenovirus Type 5-Based Vectors with a Fiber Knob-Independent Pathway for Infection 1999 ·Journal of Virology ·Emmanuelle Vigne, (unknown), Jean-François Dedieu, (unknown), Michel Perricaudet, Patrice Yeh	145
12	Reduction of Restenosis After Angioplasty in an Atheromatous Rabbit Model by Suicide Gene Therapy 1997 ·Circulation ·Philippe Gabríel Steg, (unknown), (unknown), Jean‐Michel Caillaud, Jean-François Dedieu, Karine Berthelot, Aude Le Roux, Laurent J. Feldman, Michel Perricaudet, Patrice Denèfle, Didier Branellec	64
13	In Vitro and In Vivo Hepatoma Cell-Specific Expression of a Gene Transferred with an Adenoviral Vector 1996 ·Human Gene Therapy ·Patrick Arbuthnot, Marie‐Pierre Bralet, Catherine Le Jossic-Corcos, Jean-François Dedieu, Michel Perricaudet, Christian Bréchot, Nicolas Ferry	62
14	The Epstein-Barr Virus Determined Nuclear Antigens EBNA-3A, -3B, and -3C Repress EBNA-2-Mediated Transactivation of the Viral Terminal Protein 1 Gene Promoter 1994 ·Virology ·Aude Le Roux, (unknown), Dermot Walls, Jean-François Dedieu, Michel Perricaudet	77
15	High-Titer HIV-1 Neutralizing Antibody Response of Rhesus Macaques to gp160 and env Peptides 1992 ·AIDS Research and Human Retroviruses ·(unknown), Jean-François Dedieu, (unknown), (unknown), Michel Kaczorek, Marc Girard	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact